Though spending time in the sun is generally considered a bad thing as far as skin cancer goes, it can help prevent breast cancer. A study shows that women who stay inside more often are at a high risk for breast cancer than those who spend time outside. What's more, breast cancer is less prevalent closer to the equator, where sunlight is more common. The key ingredient is the valuable Vitamin D that exposure to the sun provides, though I would be interested to know if it makes a difference whether people get natural vitamin D from the sunlight or if similar health benefits could be derived simply from staying inside and taking vitamin D supplements. I tend to think that people who get outside are generally healthier overall than those who are housebound.

This isn't the green light to spend your days cooking your skin under the hot sun in the hopes of achieving that golden brown glow, though. While sunlight in important, it's also important to take precautions in the sunlight, like covering up and wearing sunscreen.

If a desire for healthy eating is anywhere present in your mind, I have a suggestion for you. Next time you head into your local grocery store in search of goods to fill your cupboards, your shelves, your refrigerator, I want you to try this: steer clear of the inside aisles of the store.

Think about this:

The healthiest foods, the freshest foods, the whole foods are housed on the outside walls of grocery stores. Fruits, vegetables, breads, meats, dairy, and often times the organic department border the aisles filled with cookies, candies, colas, crackers, cereals, dressings, and a whole host of other preserved items. So see if you can shop without entering the less-healthy regions of your store. And if you must make a detour, shoot for the most natural foods you can find. If your search is for cooking oil, opt for canola oil instead of vegetable oil. If peanut butter is your thing, pick up natural nut butters. If you must have mayonnaise, reach for reduced fat or soy versions.

Staying on the perimeter of your store still requires some thinking -- meats should be lean, breads should start with the word whole, cheeses and dairy should be low in fat, and juices should be free of sugar. But still, this is the healthiest place for your next grocery store stroll.

If the experimental breast cancer drug Tykerb continues to prove successful in study participants, it could be headed for FDA approval.

Tykerb, now in international study, showed in early studies to be even more effective and to have fewer side effects than similar breast cancer drug Herceptin. Both drugs are part of a cluster of targeted therapies that attack cancer cells while sparing healthy cells. Designed for use on women whose breast cancer is HER2 positive -- meaning it contains too much of an aggressive protein -- Tykerb may be a wonder drug, with the capability of effectively keeping breast cancer at bay.

Dr. Paul Goss of MA General Hospital says, "We're seeing Tykerb, which is a pill, which is easier to take, has a broader attack and gets inside cells. It's like an electrical circuit that's turned on, and Tykerb can pull the lever, the circuit breaker, and switch it off."

Scientists from Harvard University and Massachusetts Institute of Technology (MIT) are developing a tiny implant that will allow doctors to see what's happening with tumors from the inside out.

If all proceeds according to plan, doctors will one day be implanting tiny sensors inside tumors to determine whether or not cancer drugs are shrinking the tumors. The sensors will also determine whether or not tumors are growing.

Cancer specialists have long wished for better methods of measuring the success of drugs. While blood tests can show if a drug has reached the bloodstream, they don't reveal much about the tumor itself. This small silicone cube, no bigger than two millimeters on each side and embedded in a tumor or lymph node, would remain in the body throughout treatment while essentially broadcasting what's going on inside the tumor.

MIT scientists hope to begin animal experiments within months. Their goal is to one day make the implant as thin as the pieces of led used in mechanical pencils.

This research, funded by the National Cancer Institute, is part of a long-term project to make medical technologies that will cure cancer. It's all part of journey toward complete targeted cancer treatment. And this little implant will have the power to communicate whether or not these treatments are working.

Women whose wedding dresses are created by bridal gown designer Aimee Lauren get a little something extra when they purchase their dream dresses. They get something of a twist -- a pink twist, in the form of a ribbon.

Each of Lauren's brides gets a pink breast cancer ribbon sewn on the inside lining over the left breast of their custom gowns -- a reminder for them to check their breasts for life. It's Lauren's way of saying, don't forget, please don't forget.

Most of Lauren's clients are young -- in their 20s and 30s -- and are not thinking of breast cancer. But they should be. Because breast cancer happens to young women -- like Lauren, who was diagnosed with the disease at a young age and in the midst of climbing the New York fashion ladder. She found a lump in her left breast during a monthly self exam. And now she is forever diligent about breast cancer awareness and early detection.

At fittings, Lauren never misses the opportunity to educate her brides about taking charge of their own health.

"I don't ever want to hear somebody say ever again that it doesn't happen to young people," she says. " It can happen to anyone."

The breast cancer drug Tykerb may be one of the future wonder drugs available for women left with limited options for treating advanced-stage disease.

Tykerb, manufactured by British-based GlaxoSmithKline PLC, is currently an experimental drug that delays growth of tumors nearly twice as long as standard chemotherapy in patients who no longer respond to Herceptin -- a targeted drug that significantly decreases chances of recurrence for women with HER2 positive breast cancer. Herceptin blocks the swift growth of an aggressive protein on the cell's surface while Tykerb does its work on the inside of the cell. Herceptin is given intravenously. Tykerb is given in pill form.

Two previous posts -- one in April and one in June -- relfect the progress of Tykerb as reported in the media. With each new report, Tykerb seems to gain momentum and promise. And this past week, new reports revealed new promise as Glaxo began seeking regulatory approval of the Tykerb pill in Europe.

Glaxo has filed an application with the Food and Drug Administration for approval of this drug and is preparing to market the drug for the treatment of advanced breast cancer in women. Glaxo hopes to launch Tykerb -- also known as lapatinib ditosylate -- next year.

Our days start early now that Joey is in kindergarten and school begins promptly at 7:45 AM. His daddy gets him out of bed at 6:30 AM so he can have some time to wake to the world before shuffling out the door, and we've happily found that Mister Rogers' Neighborhood comes on at just this time. The same Mister Rogers that first appeared on television in Canada in 1963 and then in the United States in 1967 -- with a gentle man, Mister Rogers himself, spreading his calm but uplifting messages to children and nurturing personalities of kids everywhere.

The last original episode of Mister Rogers' Neighborhood was aired in 2001. And in 2003, Fred McFeeley Rogers died at the age of 74 after a brief bout with stomach cancer. But his legacy lives on as his show -- the longest-running PBS program ever -- still graces the television screen. I remember watching this show with my grandmother when I was a little girl. And now I get to watch it with my little boy -- who can also visit Mister Rogers on the PBS website.

Today, Joey and I started our day with a cheery little song, sung by the man who hated television and joined it only to bring about change -- to use this fabulous instrument to guide children in a positive direction. And here is what he sang this morning -- the song that is still playing in my head as I take on the day ahead of me.

It's such a good feeling to know you're alive.
It's such a happy feeling: You're growing inside.
And when you wake up ready to say,
"I think I'll make a snappy new day."
It's such a good feeling, a very good feeling,
The feeling you know that we're friends.

I hope it's a good day in your neighborhood.

Stuffing your emotions, or keeping it all inside, has led more than one person down the path to trouble. At some point, if you do not express your thoughts and feelings, especially the negative ones, you stay emotionally frozen in time. It's kind of like physically clubbing yourself over the head repeatedly day after day. Of course, we cannot go around randomly screaming at people or speaking before we give ourselves time to think. There are effective ways to open up and share that will lead you to better health and help you to maintain a good relationship with family members and friends at the same time. Journaling is good, as is talk therapy or belonging to a support group.

The point is, until expressed, you are stuck with whatever you are feeling. With the passage of time, you might not even be aware of the emotions you are carrying around inside affecting you and your health, as they tend to pile up and become obscured from view.

Adelaide University psycho-neuro-immunology researcher Vikki Knott understands the benefit of letting it all out emotionally, and that sharing and releasing distressful emotions can help a cancer survivor survive cancer longer. Knott will be conducting research in emotion-focused treatments to improve cancer survivorship by charting the physical changes to the immune system before and after talk therapy sessions.

According to Knott, "It's about the link between the mind and the body and how your mind state can affect the disease state in the body." The researchers will be examining three techniques -- journaling, meditation and hypnosis. Previous research has already proven that breast cancer survivors who belong to a support group tend to live longer than their more isolated and disconnected counterparts.

Someone once told me to think of cancer as a chronic condition -- an illness like diabetes or asthma that may linger for life and may require continual treatment. And while battling cancer, perhaps for life, I should just hope that medical advances occur and new treatments become available. And maybe, just maybe, the science of medicine will decrease by leaps and bounds the number of people who die from cancer.

During my own battle with cancer -- which has been 18 months long -- two new breast cancer drugs have hit the scene with rave reviews from researchers and medical professionals. This is good news for me because my type of breast cancer makes me a candidate for both drugs. Herceptin is one of these drugs -- given to women who are HER-2/neu positive -- that's me -- and over express a protein that makes the tumor aggressive. Herceptin is received over 52 weeks -- and I go every three weeks for a 90-minute infusion of this clear liquid that causes me really no side effects at all. It can be toxic to the heart but monitoring tests have revealed that my heart is not suffering at this time. And with just three more infusions to go -- one this Wednesday -- I will likely encounter no adverse reactions to this potentially life-saving drug.

And now Tykerb is making headlines. Tykerb, suggested for use with advanced breast cancer and manufactured by British-based GlaxoSmithKline PLC, is an experimental drug that delays the growth of tumors nearly twice as long as standard chemotherapy in patients who no longer respond to Herceptin. This finding, reported this past Saturday at a meeting in Atlanta of the American Society of Clinical Oncology, confirms initial findings about the promise of this drug -- that like Herceptin, made by Genentech, precisely targets tumors without killing lots of healthy cells. The difference between the two drugs is that Herceptin blocks the protein on the cell's surface and Tykerb does it inside the cell -- blocking a second abnormal protein too. And while Herceptin is given intravenously, Tykerb is given in pill form -- which may make it cheaper and easier to use.

While now part of an international study, Tykerb may be available to women in the United States later this year. And it perhaps will be offered in conjunction with Herceptin or instead of Herceptin for women with advanced breast cancer.

I hope I do not ever need Tykerb -- and that Herceptin alone will be enough for me -- but it is comforting to know that there is something else out there. Something that if necessary, just might help me live with this potentially chronic condition called cancer.